[go: up one dir, main page]

WO2008063779A3 - Cells expressing alpha-synuclein and uses therefor - Google Patents

Cells expressing alpha-synuclein and uses therefor Download PDF

Info

Publication number
WO2008063779A3
WO2008063779A3 PCT/US2007/081227 US2007081227W WO2008063779A3 WO 2008063779 A3 WO2008063779 A3 WO 2008063779A3 US 2007081227 W US2007081227 W US 2007081227W WO 2008063779 A3 WO2008063779 A3 WO 2008063779A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
cells expressing
synuclein
expressing alpha
uses therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/081227
Other languages
French (fr)
Other versions
WO2008063779A2 (en
WO2008063779A9 (en
Inventor
Feng Liang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FoldRx Pharmaceuticals LLC
Original Assignee
FoldRx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FoldRx Pharmaceuticals LLC filed Critical FoldRx Pharmaceuticals LLC
Priority to US12/445,012 priority Critical patent/US20100122362A1/en
Priority to AU2007324138A priority patent/AU2007324138A1/en
Priority to EP07868431A priority patent/EP2087097A4/en
Priority to JP2009532601A priority patent/JP2010506569A/en
Priority to CA002683114A priority patent/CA2683114A1/en
Publication of WO2008063779A2 publication Critical patent/WO2008063779A2/en
Publication of WO2008063779A9 publication Critical patent/WO2008063779A9/en
Publication of WO2008063779A3 publication Critical patent/WO2008063779A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)

Abstract

Disclosed are mammalian neuronal cells expressing alpha synuclein as well as methods of screening to identify compounds that decrease toxicity induced by alpha synuclein expression. Compounds identified by such screens can be used to treat or prevent synucleinopathies such as Parkinson's disease, familial Parkinson's disease, Lewy body disease, the Lewy body variant of Alzheimer's disease, dementia with Lewy bodies, multiple system atrophy, or the Parkinsonism-dementia complex of Guam.
PCT/US2007/081227 2006-10-13 2007-10-12 Cells expressing alpha-synuclein and uses therefor Ceased WO2008063779A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/445,012 US20100122362A1 (en) 2006-10-13 2007-10-12 Cells expressing alpha-synuclein and uses therefor
AU2007324138A AU2007324138A1 (en) 2006-10-13 2007-10-12 Cells expressing alpha-synuclein and uses therefor
EP07868431A EP2087097A4 (en) 2006-10-13 2007-10-12 CELLS EXPRESSING ALPHA-SYNUCLEIN AND USES THEREOF
JP2009532601A JP2010506569A (en) 2006-10-13 2007-10-12 Cells expressing α-synuclein and uses thereof
CA002683114A CA2683114A1 (en) 2006-10-13 2007-10-12 Cells expressing alpha-synuclein and uses therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82932006P 2006-10-13 2006-10-13
US60/829,320 2006-10-13

Publications (3)

Publication Number Publication Date
WO2008063779A2 WO2008063779A2 (en) 2008-05-29
WO2008063779A9 WO2008063779A9 (en) 2008-07-17
WO2008063779A3 true WO2008063779A3 (en) 2008-10-23

Family

ID=39430417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/081227 Ceased WO2008063779A2 (en) 2006-10-13 2007-10-12 Cells expressing alpha-synuclein and uses therefor

Country Status (5)

Country Link
EP (1) EP2087097A4 (en)
JP (1) JP2010506569A (en)
AU (1) AU2007324138A1 (en)
CA (1) CA2683114A1 (en)
WO (1) WO2008063779A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2154153A1 (en) 2008-08-08 2010-02-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mutant alpha-synuclein, and methods using same
CN115197989A (en) * 2021-04-09 2022-10-18 中国科学院分子细胞科学卓越创新中心 Novel screening system of drug target antagonist based on cell death and activity phenotype
KR20240117150A (en) * 2021-12-17 2024-07-31 유니버시티 오브 켄트 Sequences and methods for production of recombinant biological molecules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69940024D1 (en) * 1998-10-06 2009-01-15 Univ California METHOD FOR SCREENING ANTI-AMYLOIDOGENIC PROPERTIES AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GOSAVI ET AL.: "Golgi fragmentation occures in the cells with perfibillar synuclein aggregates and procedes the formation of fibrillar inclusions", JBC, vol. 277, 2002, pages 48984 - 48992, XP008109835 *
MCLEAN ET AL.: "An alternative spliced form of roden synulcein forms intracellular inclusions in vitro: role of carbody terminus in synuclein aggregation", NEUROSCIENCE LETTERS, vol. 323, 2002, pages 219 - 223, XP008109836 *
See also references of EP2087097A4 *
SHIRASAKI ET AL.: "Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice", ACTA NEUROPATHOL., vol. 112, 2006, pages 681 - 689, XP019442880 *
TANAKA ET AL.: "Inducible expression of mutant alpha synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis", HUMAN MOLECULAR GENETICS, vol. 10, 2001, pages 919 - 926, XP002903519 *
VAN DER PUTTEN ET AL.: "Neuropathology in mice expressing human synuclein", JOURNAL OF NEUROSCIENCE, vol. 20, 2000, pages 6021 - 6029, XP002983611 *

Also Published As

Publication number Publication date
CA2683114A1 (en) 2008-05-29
WO2008063779A2 (en) 2008-05-29
AU2007324138A1 (en) 2008-05-29
JP2010506569A (en) 2010-03-04
EP2087097A4 (en) 2010-02-03
WO2008063779A9 (en) 2008-07-17
EP2087097A2 (en) 2009-08-12

Similar Documents

Publication Publication Date Title
HUE040654T2 (en) Methods and organisms for the growth-coupled production of 1,4-butanediol
CL2012001956A1 (en) Compounds derived from substituted triazole, gamma secretase modulators; pharmaceutical composition; and its use in the treatment or prevention of a disease such as Alzheimer's, traumatic brain injury, dementia associated with Parkinson's disease, among others.
WO2010048149A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
IL184524A0 (en) Substituted pyrazolo-pyridines, compositions containing them, method for the production thereof, and their use
WO2008099210A3 (en) Piperazine derivatives for treatment of ad and related conditions
CR10852A (en) BICYCLE COMPOUNDS AND ITS USE AS ANTI-DIABETICS
EP1937821A4 (en) Methods and organisms for the growth-coupled production of succinate
SG176656A1 (en) Microorganisms for the production of 1,4-butanediol and related methods
IL189500A0 (en) Diaminopyrimidines as p2x3 and p3x2/3 modulators
ATE451364T1 (en) AZABICYCLOÄ3.1.0ÜHEXANE DERIVATIVES SUITABLE AS MODULATORS OF THE DOPAMINE D3 RECEPTOR
EP1990374A4 (en) C. I. 57: 1 RED PIGMENT AND PROCESS FOR PRODUCING THE SAME
CL2011001098A1 (en) Compounds derived from 4-fluoro-1h-isoindol-3-amine; b-secretase (bace) inhibitors; pharmaceutical composition; and its use for the treatment or prevention of a pathology related to beta amyloid protein such as down syndrome, Alzheimer's, senile dementia and dementia associated with parkinson's, among others.
EP1931369A4 (en) METHODS FOR REDUCING THE EXPRESSION OF CD36
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
WO2011016861A3 (en) Novel regulatory proteins and inhibitors
PL2401263T3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
IL200029A0 (en) Methods for the treatment of senile dementia of the alzheimer's type
WO2007122382A3 (en) Lycopene for the treatment of metabolic dysfunction
WO2008063779A3 (en) Cells expressing alpha-synuclein and uses therefor
BRPI0821026A2 (en) Alpha-Minoamide Derivatives Useful in the Treatment of Psychiatric Disorders
WO2010048710A8 (en) Neurotoxic sterol glycosides
EP1884514A4 (en) Method for the resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazol and intermediate compounds
WO2009151618A3 (en) Methods and compositions for treating alzheimer's disease
IL185499A0 (en) Cosmetic composition enriched with 1 h2 16o
WO2008094697A8 (en) Disc augmentation with hyaluronic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07868431

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2683114

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007324138

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009532601

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007868431

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007324138

Country of ref document: AU

Date of ref document: 20071012

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12445012

Country of ref document: US